IQVIA Holdings Inc. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. IQVIA Holdings Inc. is a leading global provider of clinical research services, commercial insights, and healthcare intelligence. Effective January 1, 2026, the company reorganized its reporting structure from three segments to two: Commercial Solutions and Research & Development Solutions. The company employs approximately 93,000 people across more than 100 countries.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $4,151 million | $3,829 million |
| Net Income (Attributable to IQVIA) | $274 million | $249 million |
| Diluted EPS | $1.61 | $1.40 |
| Operating Cash Flow | $618 million | $568 million |
| Total Debt (Principal) | $15,908 million | $15,800 million |
| Cash and Equivalents | $1,947 million | $1,740 million |
| Operating Margin | 12.4% | 13.0% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8.4% year-over-year, driven by constant currency growth of 6.0%. Commercial Solutions grew 11.6% (8.5% constant currency), while Research & Development Solutions grew 6.2% (4.2% constant currency).
- Profitability: Net income rose 10.0% to $274 million. Operating income increased to $514 million, though operating margin compressed slightly due to higher restructuring costs ($51 million vs. $29 million) and increased depreciation/amortization.
- Segment Profit: Commercial Solutions segment profit increased 7.3% to $381 million. Research & Development Solutions segment profit decreased slightly by 0.8% to $472 million.
- Debt Management: The company issued a $650 million Term Loan in March 2026 to repay maturing Euro-denominated senior notes. Total debt principal increased slightly to $15.9 billion.
- Share Repurchases: The company repurchased 3.2 million shares for $552 million during the quarter.
Outlook, Risks, and Unusual Items
- Backlog: Research & Development Solutions contracted backlog increased to $34.2 billion as of March 31, 2026, with approximately $8.9 billion expected to convert to revenue in the next 12 months. Total remaining performance obligations are approximately $37.3 billion.
- Restructuring: The company continues restructuring actions to align resources and reduce overcapacity. Costs of $51 million were incurred in Q1 2026, with actions expected to continue into 2027.
- Tax Environment: The effective tax rate was 18.0% in Q1 2026 (vs. 18.9% in Q1 2025). The company is monitoring the impact of OECD Pillar Two global minimum tax rules, which became effective in 2025.
- Risks: Key risks include foreign currency fluctuations (approx. 30% of revenue is non-USD), potential contract terminations, regulatory changes in data privacy, and the ability to successfully integrate acquired businesses.
Investor Verification Checklist
- Verify the sustainability of the 6.0% constant currency revenue growth rate across both segments.
- Monitor the execution of ongoing restructuring plans and their impact on future operating margins.
- Assess the impact of the new segment structure on future performance reporting and comparability.
- Review the conversion rate of the $34.2 billion backlog into actual revenue over the coming quarters.
- Track the company's compliance with debt covenants, particularly the net leverage ratio, given the $15.9 billion debt load.